Equities

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.62
  • Today's Change-2.40 / -26.61%
  • Shares traded1.11m
  • 1 Year change-37.25%
  • Beta0.9905
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.

  • Revenue in CNY (TTM)691.62m
  • Net income in CNY105.20m
  • Incorporated1996
  • Employees948.00
  • Location
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LtdZhangjiang Hi-tech ParkNo.308 Cailun RoadPudong District, Zhangjiang Hi-tech ParkSHANGHAI 201210ChinaCHN
  • Phone+86 2 158553583
  • Fax+86 2 158553893
  • Websitehttp://www.fd-zj.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sichuan Huiyu Pharmaceutical Co Ltd1.12bn278.20m6.98bn1.36k25.081.80--6.230.65670.65672.649.160.23351.1821.25820,954.905.6610.417.0812.7683.4089.8924.2321.422.57--0.148820.54-37.9276.37-43.86--66.72--
Jianmin Pharmaceutical Group Co Ltd3.98bn427.95m7.05bn2.50k16.422.94--1.772.802.8025.9815.610.97936.994.161,592,652.0010.6210.8718.4919.1142.3443.0410.849.321.38--0.149237.1515.7214.2827.7845.058.7743.10
Wuhan Keqian Biology Co Ltd902.14m299.11m7.17bn923.0024.021.86--7.950.64040.64041.938.280.19682.442.47977,402.106.5113.297.6215.4963.8776.4933.0845.714.71--0.020924.766.277.67-3.320.355627.17--
Zhejiang Ausun Pharmaceutical Co Ltd835.23m257.55m7.23bn1.17k28.003.15--8.660.31110.31111.012.760.27881.092.84711,439.108.609.3811.3512.8454.3453.0930.8427.142.00--0.15623.536.8327.357.8742.0724.3250.48
Shanghai Fudan-Zhangjiang Bio-Pharm. Co691.62m105.20m7.29bn948.0090.343.98--10.540.09980.09980.65092.270.24821.531.50729,558.103.767.034.439.0590.2492.1715.1517.266.06--0.004826.31-17.502.78-21.28-0.632620.49--
Lushang Freda Pharmaceutical Co Ltd3.99bn236.52m7.35bn3.65k31.081.80--1.840.23270.23273.924.020.46940.79417.741,091,879.003.230.69925.935.1248.7320.236.873.452.96--0.089640.33-64.65-12.29567.4413.3644.4014.87
China Animal Husbandry Industry Co., Ltd5.43bn87.90m7.36bn4.33k83.771.34--1.360.08610.08615.315.370.61274.563.761,254,216.000.70856.231.009.0116.4224.291.168.691.54--0.190931.20-8.244.04-26.73-0.612724.20-3.77
JiangSu WuZhong Pharmactcl Devlpm Co Ltd2.38bn-37.82m7.40bn1.05k--4.12--3.10-0.055-0.0553.342.520.568417.732.042,270,402.00-0.8772-2.92-1.79-5.3028.0728.14-1.54-5.771.460.51270.4841--10.555.655.58---19.08--
Data as of Sep 13 2024. Currency figures normalised to Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.07%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 30 Jun 2024261.41k0.04%
Penghua Fund Management Co., Ltd.as of 30 Jun 2024128.82k0.02%
Tebon Fund Management Co. Ltd.as of 30 Jun 202477.70k0.01%
Dimensional Fund Advisors Ltd.as of 31 Jul 202439.44k0.01%
Yinhua Fund Management Co., Ltd.as of 30 Jun 2024752.000.00%
Orient Fund Management Co., Ltd.as of 30 Jun 2024649.000.00%
China Universal Asset Management Co., Ltd.as of 30 Jun 20240.000.00%
CCB Principal Asset Management Co., Ltd.as of 29 Feb 20240.000.00%
CITIC Securities Co., Ltd. (Invt Port)as of 30 Jun 20240.000.00%
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.